PD-1/VEGF三抗崛起

药智网2025-07-09

随着康方生物依沃西挑战PD-1单抗成功，肿瘤免疫疗法（IO）快速迭代至2.0时代，PD-(L)1/VEGF双抗受到MNC抢购，而PD-(L)1/VEGF三特异性抗体也逐渐成为研发热潮，预示着肿瘤治疗正加速向多靶点协同方向演进。近日，基石药业宣布，其自主研发的潜在同类首创/同类最佳的CS2009（PD-1/VEGF/CTLA-4三特异性抗体）最新临床进展。该药具有均衡的单价PD-1和CTLA-4结合...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2550562505?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-09 10:26","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2550562505","market":"hk","top_or_hot":-1,"title":"PD-1/VEGF三抗崛起","media":"药智网","content":"<div>\n<p>随着康方生物依沃西挑战PD-1单抗成功，肿瘤免疫疗法（IO）快速迭代至2.0时代，PD-(L)1/VEGF双抗受到MNC抢购，而PD-(L)1/VEGF三特异性抗体也逐渐成为研发热潮，预示着肿瘤治疗正加速向多靶点协同方向演进。近日，基石药业宣布，其自主研发的潜在同类首创/同类最佳的CS2009（PD-1/VEGF/CTLA-4三特异性抗体）最新临床进展。该药具有均衡的单价PD-1和CTLA-4结合...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102835a69e4925&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PD-1/VEGF三抗崛起</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPD-1/VEGF三抗崛起\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-09 10:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102835a69e4925&s=b><strong>药智网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>随着康方生物依沃西挑战PD-1单抗成功，肿瘤免疫疗法（IO）快速迭代至2.0时代，PD-(L)1/VEGF双抗受到MNC抢购，而PD-(L)1/VEGF三特异性抗体也逐渐成为研发热潮，预示着肿瘤治疗正加速向多靶点协同方向演进。近日，基石药业宣布，其自主研发的潜在同类首创/同类最佳的CS2009（PD-1/VEGF/CTLA-4三特异性抗体）最新临床进展。该药具有均衡的单价PD-1和CTLA-4结合...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102835a69e4925&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102835a69e4925&s=b","article_id":"2550562505","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102835a69e4925&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2550562505","pubTimestamp":1752027983,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，基石药业宣布，其自主研发的潜在同类首创/同类最佳的CS2009最新临床进展。该药具有均衡的单价PD-1和CTLA-4结合臂以及双价VEGFA结合臂，可产生强效多靶点协同效应以及优先靶向肿瘤组织以降低系统性毒性。除了基石药业的CS2009，上海宏成药业也开发了一款PD-1/CTLA-4/VEGF的三特异性抗体HC010，目前正在进行一项评估HC010治疗晚期实体瘤患者的安全性、药代动力学和抗肿瘤活性的多中心、开放、剂量递增和剂量扩展I期临床研究。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1161":"生物科技","02616":"基石药业-B"},"translate_title":"The rise of PD-1/VEGF tertiary antibodies","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":0.9},"content_text":"随着康方生物依沃西挑战PD-1单抗成功，肿瘤免疫疗法（IO）快速迭代至2.0时代，PD-(L)1/VEGF双抗受到MNC抢购，而PD-(L)1/VEGF三特异性抗体也逐渐成为研发热潮，预示着肿瘤治疗正加速向多靶点协同方向演进。近日，基石药业宣布，其自主研发的潜在同类首创/同类最佳的CS2009（PD-1/VEGF/CTLA-4三特异性抗体）最新临床进展。该药具有均衡的单价PD-1和CTLA-4结合臂以及双价VEGFA结合臂，可产生强效多靶点协同效应以及优先靶向肿瘤组织以降低系统性毒性。CS2009的全球多中心I/II期临床研究正在澳大利亚和中国积极招募患者，并计划扩展至美国进行II期入组。目前，该试验入组非常迅速，预计年底前患者数将突破100例。Ia期剂量递增研究已在多线经治的晚期实体瘤患者中完成了四个剂量水平的评估，当前正在第五剂量水平（30毫克/千克，每三周给药一次）入组患者。Ib期/II期剂量扩展研究/关键延展研究预计将于2025年下半年启动。截至目前，CS2009在所有已评估的剂量水平上展现出良好的耐受性，并且已在低剂量组的“冷肿瘤”及PD-(L)1经治患者中观察到抗肿瘤活性。Ia期临床数据（包括安全性、PK，PD和抗肿瘤活性）预计将于2025年第四季度国际学术会议上公布。除了基石药业的CS2009，上海宏成药业也开发了一款PD-1/CTLA-4/VEGF的三特异性抗体HC010，目前正在进行一项评估HC010治疗晚期实体瘤患者的安全性、药代动力学和抗肿瘤活性的多中心、开放、剂量递增和剂量扩展I期临床研究。表1 全球在研PD-(L)1/VEGF双抗/多抗药物数据来源：药智数据声明：本内容仅用作医药行业信息传播，不代表药智网立场。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2550562505","isCrawlerRequest":true}